Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Ex vivo expansion of hematopoietic stem and progenitor cells from human mobilized peripheral blood for gene therapy applications.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Human haematopoietic stem cells remember inflammatory stress.

Nature·2026
Same author

ATP2B1 expression identifies human hematopoietic stem cells with superior repopulation and self-renewal.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Transposable elements shape stemness in normal and leukemic hematopoiesis.

Nature genetics·2026
Same author

In-patient management of dislocation after total hip arthroplasty: a multicentre study from UK hospitals.

Hip international : the journal of clinical and experimental research on hip pathology and therapy·2026
Same journal

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same journal

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same journal

Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry.

Blood advances·2026
Same journal

Diagnosis of NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
Same journal

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same journal

Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis.

Blood advances·2026
See all related articles

Related Experiment Video

Updated: Dec 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.4K

CD200 expression marks leukemia stem cells in human AML.

Jenny M Ho1,2, Stephanie M Dobson1, Veronique Voisin3

  • 1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Blood Advances
|November 4, 2020
PubMed
Summary
This summary is machine-generated.

CD200 is a novel marker for identifying leukemia stem cells (LSCs) in acute myeloid leukemia (AML). This marker captures the full spectrum of LSCs, aiding in understanding therapy resistance and relapse in AML patients.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.5K
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

7.6K

Related Experiment Videos

Last Updated: Dec 2, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.4K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.5K
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

7.6K

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunophenotyping

Background:

  • Leukemia stem cells (LSCs) in acute myeloid leukemia (AML) are heterogeneous, contributing to treatment failure.
  • Isolating the complete LSC population for research has been challenging.
  • Previous work indicated CD200 upregulation in LSC-enriched AML fractions.

Purpose of the Study:

  • To identify a reliable marker for isolating the heterogeneous leukemia stem cell (LSC) population in acute myeloid leukemia (AML).
  • To investigate the utility of CD200 as a marker for capturing the entire LSC compartment.
  • To assess if CD200 can identify LSCs across different AML subtypes, including CD34- and NPM1-mutated cases.

Main Methods:

  • Flow cytometry analysis of CD200 expression on AML blasts (CD45dim vs. CD45high).
  • Xenotransplantation assays to assess the LSC activity of CD200+ cells.
  • Isolation of CD200+ LSCs from normal hematopoietic stem cells (HSCs) using additional markers.
  • Gene expression profiling of purified CD200+ LSC fractions from NPM1-mutated AML.

Main Results:

  • CD200 is expressed on a higher proportion of CD45dim blasts in AML samples.
  • CD200 identified LSCs in 90% of tested AML samples.
  • CD200 successfully isolated both CD34+ and CD34+ LSCs, including those in NPM1-mutated AML.
  • Purified CD200+ LSCs from NPM1-mutated AML showed enrichment of primitive gene signatures.

Conclusions:

  • CD200 serves as a novel and effective marker for capturing the heterogeneous leukemia stem cell (LSC) compartment in AML.
  • This marker facilitates the isolation of LSCs across diverse AML subtypes, including CD34- and NPM1-mutated cases.
  • CD200+ LSCs represent a valuable target for understanding and overcoming therapy resistance in AML.